Use of circulating tumor DNA to guide adjuvant treatment planning for patients with resectable colon cancer led to fewer patients receiving chemotherapy while maintaining outcomes, according to the DYNAMICS study.
Use of circulating tumor DNA to guide adjuvant treatment planning for patients with resectable colon cancer led to fewer patients receiving chemotherapy while maintaining outcomes, according to the DYNAMICS study.
Comments are closed.